Preclinical Safety Pharmacological Studies on the Amorphous Formulation of Celecoxib

Abstract

Safety pharmacological studies need to be performed according to ICH S7A Guidelines for finished formulations that substantially alter the pharmacokinetics and/or pharmacodynamics of the active substance in comparison to formulations previously tested (i. e. through active excipients such as penetration enhancers, liposomes, and other changes such as polymorphous system). In the present study, amorphous formulation of celecoxib (CAS 169590-42-5), a new patented formulation with altered pharmacokinetic profile was investigated in comparison with the standard crystalline celecoxib (CEL) for its undesirable pharmacodynamic effects using certain safety pharmacological studies. The effects of the new formulation on vital functions using safety pharmacology core battery like central nervous system (CNS) (functional observation battery, locomotor activity, and motor coordination) and cardiovascular system (CVS) (blood pressure, heart rate and QT interval) were investigated in laboratory rodents. In addition, supplementary safety pharmacology study on gastrointestinal system (GIT) (gastric injury potential, gastric secretion) was also carried out. Oral administration of a single dose of the amorphous celecoxib formulation (CF) varying of 50, 150 and 500 mg/kg was studied in comparison with vehicle treated control and crystalline celecoxib in animals. The maximum tolerated dose (MTD) was identified by administration of insufferable doses of amorphous formulation, extended up to 2 000 mg/kg during the experiments on physiological parameters. There were no CNS and GIT safety concerns raised with respect to use of CF except the arrythmogenic risk associated with QT interval prolongation upon the high dose of CF.

Key words

CAS 169590-42-5 - Celecoxib, amorphous formulation - Core battery safety pharmacology - COX-2 inhibitors - Functional observation battery - Non steroidal anti-inflammatory drugs

• Literature

• 1 Frampton JE, Keating GM. Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs. 2007; 67: 2433-2472
• 2 Barden J, Edwards JE, McQuay HJ, Moore RA. Single dose oral celecoxib for postoperative pain. Cochrane Database Syst Rev. 2008; CD004233: 1-11
• 3 Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006; 355: 885-895
• 4 Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001; 297: 638-645
• 5 Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharm Res. 2000; 17: 397-404
• 6 Bansal AK, Gupta P, Kakumanu VK. Ternary amorphous systems for improving aqueous solubility of poorly water soluble drugs. Indian Pat. Appl 2008; IN 2002DE00682: 1-10
• 7 Gupta P, Bansal AK. Oral bioavailability advantage from stabilized amorphous systems of celecoxib. J Pharm Res. 2006; 5: 1-9
• 8 Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation. 2006; 113: 1950-1957
• 9 Solomon SD, McMurray JV, Pfeffer MA, Wittes J, Fowler R, Finn P et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071-1080
• 10 Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000; 284: 1247-1255
• 11 Center for Drug Evaluation and Research (CDER), US FDA. Guidance for industry: S7A safety pharmacology studies for human pharmaceuticals. July 2001. Available at http://www.fda.gov/CDER/GUIDANCE/4461fnl.pdf
• 12 Hübler N, Gottschling B, Jacobs M, von Landenberg F, Hewicker-Trautwein M. Functional observational battery and motor activity in rats after single administration of two NHE 1 inhibitors. Toxicol Appl Pharmacol. 2005; 208: 266-276
• 13 Moser VC. Neurobehavioral screening in rodents. Mahin M, Costa LG, Reed DJ, Shigeru SI, Glenn S. eds Curr Protoc Toxico. New Jersey: John Wiley & Sons, Inc; 2000
• 14 Gupta S, Sharma SS. Neuroprotective effects of trolox in global cerebral ischemia in gerbils. Biol Pharm Bull. 2006; 29: 957-961
• 15 Kim EJ, Lee RK, Suh JE, Han SS, Kim JK. Safety pharmacology of CKD-602, a novel anticancer agent. Arzneimittelforschung. 2003; 53: 272-279
• 16 Arun KHS, Kaul CL, Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res. 2005; 65: 374-386
• 17 Hamlin RL, Kijtawornrat A, Keene BW, Hamlin DM. QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicol Sci. 2003; 76: 437-442
• 18 Hamlin RL. Non-drug-related electrocardiographic features in animal models in safety pharmacology. J Pharmacol Toxicol Methods. 2005; 52: 60-76
• 19 Luo JC, Shin VY, Liu ESL, So WHL, Ye YN, Chang FY et al. Non-ulcerogenic dose of dexamethasone delays gastric ulcer healing in rats. J Pharmacol Exp Ther. 2003; 307: 692-698
• 20 Ito K, Kinoshita K, Tomizawa A, Inaba F, Morikawa-Inoma-ta Y, Makino M et al. Pharmacological profile of novel acid pump antagonist 7-(4-Fluorobenzyloxy)-2,3-dimethyl-l-{[(lS,2S)-2-methyl cyclopropyl]methyl}-lH-pyrrolo[2,3-d]-pyridazine (CS-526). J Pharmacol Exp Ther. 2007; 323: 308-317
• 21 Arisawa H, Fukui K, Imai E, Fujise N, Masunaga H. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjogren’s syndrome. 4th communication: effects on gastrointestinal, urinary and reproductive systems and other effects. Arzneimittelforschung. 2002; 52: 225-232
• 22 Center for Drug Evaluation and Research (CDER), US FDA. Guidance for industry: S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Rockville, October 2005. Available at http://www.fda.gov/CDER/GUIDANCE/6885fnl.pdf
• 23 Monro A, Mordenti J. Expression of exposure in negative carcinogenicity studies: dose/body weight, dose/body surface area, or plasma concentrations?. Toxicol Pathol. 1995; 23: 187-198
• 24 Voisin EM, Ruthsatz M, Collins JM, Hoyle PC. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. Regul Toxicol Pharmacol. 1990; 12: 107-116
• 25 Sakaguchi Y, Sugiyama A, Takao S, Akie Y, Takahara A, Hashimoto K. Halothane sensitizes the guinea-pig heart to pharmacological IKr blockade: comparison with urethane anesthesia. J Pharmacol Sci. 2005; 99: 185-190
• 26 Takahara A, Sugiyama A, Hashimoto K. Characterization of the halothane-anesthetized guinea-pig heart as a model to detect the K⁺ channel blocker-induced QT-interval prolongation. Biol Pharm Bull. 2006; 29: 827-829
• 27 Netzer R, Ebneth A, Bischoff U, Pongs O. Screening lead compounds for QT interval prolongation. Drug Discov Today. 2001; 6: 78-84
• 28 Peskar B. Role of cyclooxygenase isoforms in gastric mucosal defense and ulcer healing. Inflammopharmacology. 2005; 13: 15-26
• 29 Takahashi S, Shigeta J, Inoue H, Tanabe T, Okabe S. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. Am J Physiol Gastrointest Liver Physiol. 1998; 275: G1137-1145